Literature DB >> 16227243

Analysis of a highly flexible conformational immunogenic domain a in hepatitis C virus E2.

Zhen-Yong Keck1, Ta-Kai Li, Jinming Xia, Birke Bartosch, François-Loïc Cosset, Jean Dubuisson, Steven K H Foung.   

Abstract

Hepatitis C (HCV) E2 glycoprotein is involved in virus attachment and entry, and its structural organization is largely unknown. Characterization of a panel of human monoclonal antibodies (HMAbs) to HCV by competition studies has led to an immunogenic organization model of E2 with three domains designated A, B, and C and epitopes in each domain having similar structural and functional properties. Domain A contains nonneutralizing epitopes, and domains B and C contain neutralizing epitopes. The isolation and characterization of three new HMAbs within domain A for a total of six provide support for this model. All six domain A HMAbs do not neutralize HCV retroviral pseudotype particle (HCVpp) infection on Huh-7 cells, and all six HMAbs have similar binding affinity and maximum binding, B(max), a relative indicator of epitope density, as other neutralizing HMAbs, suggesting that neutralization is epitope specific and not by binding to any surface epitope. The dose-dependent neutralizing activity of CBH-7, an HMAb to a domain C epitope in spatial proximity to domain A, and of CBH-5, a domain B HMAb to a more distant epitope, were tested in the presence and absence of each domain A HMAb. No enhancement or reduction in CBH-7 or CBH-5 neutralizing activity was observed, indicating that the potential induction of nonneutralizing antibodies should not be a central issue for HCV vaccine design. To assess whether domain A is involved in the structural changes as part of a pH-dependent virus envelope fusion process, changes in antibody binding patterns to normal pH and acid pH-treated HCVpp were measured. Antibody binding affinity of HMAbs to HCVpp was not affected by low pH. However, the B(max) values for low-pH-treated HCVpp with antibodies to domain A increased 46%, for domain C (CBH-7) they increased 23%, and for domain B (CBH-5) there was a decrease of 12%. Collectively, the organization and function of HCV E2 antigenic domains are roughly analogous to the large envelope glycoprotein E organizational structure for other flaviviruses with three distinct structural and functional domains.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227243      PMCID: PMC1262592          DOI: 10.1128/JVI.79.21.13199-13208.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy.

Authors:  B Robertson; G Myers; C Howard; T Brettin; J Bukh; B Gaschen; T Gojobori; G Maertens; M Mizokami; O Nainan; S Netesov; K Nishioka; T Shin i; P Simmonds; D Smith; L Stuyver; A Weiner
Journal:  Arch Virol       Date:  1998       Impact factor: 2.574

2.  The Fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH.

Authors:  J Lescar; A Roussel; M W Wien; J Navaza; S D Fuller; G Wengler; G Wengler; F A Rey
Journal:  Cell       Date:  2001-04-06       Impact factor: 41.582

Review 3.  CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system.

Authors:  S Levy; S C Todd; H T Maecker
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

4.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

Authors:  V Agnello; G Abel; M Elfahal; G B Knight; Q X Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

5.  The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution.

Authors:  F A Rey; F X Heinz; C Mandl; C Kunz; S C Harrison
Journal:  Nature       Date:  1995-05-25       Impact factor: 49.962

Review 6.  The molecular basis of virulence of the encephalitogenic flaviviruses.

Authors:  P C McMinn
Journal:  J Gen Virol       Date:  1997-11       Impact factor: 3.891

7.  Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes.

Authors:  K G Hadlock; R E Lanford; S Perkins; J Rowe; Q Yang; S Levy; P Pileri; S Abrignani; S K Foung
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

8.  A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.

Authors:  D Rosa; S Campagnoli; C Moretto; E Guenzi; L Cousens; M Chin; C Dong; A J Weiner; J Y Lau; Q L Choo; D Chien; P Pileri; M Houghton; S Abrignani
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-05       Impact factor: 11.205

9.  A model for the hepatitis C virus envelope glycoprotein E2.

Authors:  A T Yagnik; A Lahm; A Meola; R M Roccasecca; B B Ercole; A Nicosia; A Tramontano
Journal:  Proteins       Date:  2000-08-15

10.  Low density lipoprotein receptor as a candidate receptor for hepatitis C virus.

Authors:  M Monazahian; I Böhme; S Bonk; A Koch; C Scholz; S Grethe; R Thomssen
Journal:  J Med Virol       Date:  1999-03       Impact factor: 2.327

View more
  56 in total

1.  Affinity maturation to improve human monoclonal antibody neutralization potency and breadth against hepatitis C virus.

Authors:  Yong Wang; Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Fraser Conrad; Jianlong Lou; Michael Eckart; James D Marks; Steven K H Foung
Journal:  J Biol Chem       Date:  2011-10-14       Impact factor: 5.157

2.  Computational Prediction of the Heterodimeric and Higher-Order Structure of gpE1/gpE2 Envelope Glycoproteins Encoded by Hepatitis C Virus.

Authors:  Holly Freedman; Michael R Logan; Darren Hockman; Julia Koehler Leman; John Lok Man Law; Michael Houghton
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

3.  Expression and characterization of a minimal hepatitis C virus glycoprotein E2 core domain that retains CD81 binding.

Authors:  Kathleen McCaffrey; Irene Boo; Pantelis Poumbourios; Heidi E Drummer
Journal:  J Virol       Date:  2007-06-20       Impact factor: 5.103

Review 4.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

5.  Hypervariable region 1 shielding of hepatitis C virus is a main contributor to genotypic differences in neutralization sensitivity.

Authors:  Jannick Prentoe; Rodrigo Velázquez-Moctezuma; Steven K H Foung; Mansun Law; Jens Bukh
Journal:  Hepatology       Date:  2016-08-09       Impact factor: 17.425

Review 6.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

7.  Mapping a region of hepatitis C virus E2 that is responsible for escape from neutralizing antibodies and a core CD81-binding region that does not tolerate neutralization escape mutations.

Authors:  Zhen-Yong Keck; Anasuya Saha; Jinming Xia; Yong Wang; Patrick Lau; Thomas Krey; Felix A Rey; Steven K H Foung
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

Review 8.  Adaptive immunity to the hepatitis C virus.

Authors:  Christopher M Walker
Journal:  Adv Virus Res       Date:  2010       Impact factor: 9.937

9.  Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein.

Authors:  Zhenyong Keck; Wenyan Wang; Yong Wang; Patrick Lau; Thomas H R Carlsen; Jannick Prentoe; Jinming Xia; Arvind H Patel; Jens Bukh; Steven K H Foung
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

10.  A point mutation leading to hepatitis C virus escape from neutralization by a monoclonal antibody to a conserved conformational epitope.

Authors:  Zhen-Yong Keck; Oakley Olson; Meital Gal-Tanamy; Jinming Xia; Arvind H Patel; Marlène Dreux; Francois-Loïc Cosset; Stanley M Lemon; Steven K H Foung
Journal:  J Virol       Date:  2008-04-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.